The core difficulty is architectural. The noncoding genome is not read linearly: cis-regulatory elements such as enhancers can lie more than a million base pairs away from the genes they control, often buried inside the introns of unrelated genes. Enhancers, bound by clusters of transcription factors, physically loop through three-dimensional space to contact promoters near transcription start sites, and the specificity of these contacts is shaped by CTCF-bound boundary elements operating through cohesin-mediated loop extrusion. Chromatin structure is therefore a key determinant of gene expression, but conventional chromosome conformation capture (3C) methods, which rely on restriction enzymes that cut only at specific sequence motifs, cannot resolve contacts below roughly 500 base pairs and cannot generate single-allele data for most variants. Only about 30 percent of variants lie close enough to a restriction cut site to be studied at all.

The Oxford group, led by James Davies together with Jim Hughes and Thomas Milne, developed a variant-to-function platform called Micro Capture-C variant-to-function, or MCCv, built on their earlier Micro Capture-C method. Instead of restriction enzymes, the technique uses micrococcal nuclease to fragment chromatin, allowing data to be generated from any site of interest. Oligonucleotide probes are designed directly over the variant being tested, and ultra-short-range ligation junctions of less than 800 base pairs define the nanoscale topology at the variant itself, while long-range junctions spanning one kilobase to one megabase define the structure of the whole locus. The result is the highest-resolution 3C data produced to date, capable of resolving chromatin architecture at the level of individual transcription factor binding sites while simultaneously identifying the target genes contacted by each regulatory element.

The single-allele capability is what makes the platform powerful for genetics. In cells that are heterozygous for a variant, the reference and alternate chromosomes can be separated computationally, so each allele effectively serves as an internal control for the other, minimizing experimental noise. In benchmarking experiments on 42 heterozygous gain-of-function enhancer variants in Jurkat cells, inactive reference alleles displayed a regular nucleosomal patterning, whereas active alternate alleles showed distinctive fine-scale contact patterns consistent with transcription factor interactions within nucleosome-depleted regions. The method captured 86.7 percent of reads for allelic analysis, and analysis of the rheumatoid arthritis-associated variant rs2793109 revealed that the disease allele creates a RUNX1 motif with a complex pattern of short-range contacts, while simultaneously showing allele-specific changes in long-range interactions with the promoters of ZEB1 and ZNF438. By phasing the captured variant with other heterozygous SNPs across the locus, the team linked the risk allele to increased ZEB1 expression using intron-rich RNA sequencing.

Applied systematically to immune-mediated inflammatory disease genetics, the platform delivered striking results. Single-cell ATAC-seq analysis showed that CD4-positive T cells, particularly central memory T cells, carry the highest burden of IMID-associated variation. The researchers imputed 3,104 independent haplotypes from 400 studies and tested each variant within them for molecular mechanisms, assigning a potential causal variant and mechanism to 47 percent of haplotypes, including 405 unique enhancer variants. Deep MCCv capture in activated primary CD4-positive T cells then mapped enhancer-promoter contacts with a sensitivity far beyond genome-wide methods: the strongest contact for each variant was supported by a mean of roughly 839 ligation junctions, compared with an average of just 2.5 junctions from Micro-C, and a fivefold better signal-to-noise ratio. At the 1q24.3-25.1 locus, four independent disease signals mapped to four distinct regulatory elements, with the eczema enhancer contacting FASL and the vitiligo, celiac disease and Crohn’s disease enhancers contacting TNFSF14 while skipping the intervening TNFSF18 promoter.

Ranking promoters by contact frequency allowed the team to nominate 251 unique causal genes, and these clustered in key immune pathways and were enriched for tractable drug targets and rare primary immunodeficiency mutations. Notably, only 60.5 percent of variants contacted their nearest gene most strongly, underscoring how misleading nearest-gene assumptions can be. Single-allele analysis of the 405 captured regulatory elements showed that 54.6 percent of heterozygous disease-associated variants had at least one significantly altered contact, and disease variants showed far greater architectural changes than matched controls for cell type, haplotype and disease association. When the researchers paired these contact data with phased RNA sequencing, variants with detectable changes in allelic contact frequency were roughly threefold enriched for allelic imbalance in expression of their nominated genes, with directional concordance between the chromatin and RNA effects at up to 88.2 percent of well-phased pairs.

The centerpiece discovery came from the rs4409785 variant at the 11q21 locus, associated with multiple sclerosis, rheumatoid arthritis and several other autoimmune conditions. Motif analysis showed that the disease-associated allele creates an entirely new CTCF binding site, a neo-CTCF motif, and the reference allele is conserved throughout hominin and primate evolution, confirming that the risk allele is a gain of function. MCCv footprinting revealed a precise 20-base-pair footprint over the CTCF motif only on the alternate allele, and CTCF ChIP-seq and ATAC-seq from heterozygous donors confirmed increased CTCF binding and open chromatin there. To prove causality, the team coupled the platform with genome editing: using the cytosine base editor BE4max in primary CD4-positive T cells from a heterozygous donor, they mutated three critical bases of the CTCF motif while leaving the variant itself intact. A single experiment yielded six separable profiles, and editing the motif on the risk allele reverted both the long-range contacts to convergent downstream CTCF sites and the nanoscale chromatin structure to the inert nucleosomal pattern of the reference chromosome.

The mechanistic consequence was unexpected. Neither allele of rs4409785 contacts any gene promoter directly; instead, the neo-CTCF site forms a subdomain that walls off a T cell-specific super-enhancer lying between the FAM76B and SESN3 genes. Phased MCCv from the SESN3 promoter showed that the risk allele significantly reduces contacts between that super-enhancer and the SESN3 promoter, and phased RNA sequencing linked the variant to a 36.6 percent reduction in SESN3 transcript on the risk chromosome. SESN3 encodes Sestrin 3, the least-characterized member of a family known to inhibit mTOR signaling, a central pathway controlling immune cell activation. In primary human T cells, SESN3 knockout left mTOR signaling unchanged under normal conditions but increased it under amino acid starvation. Using an endogenously tagged cell line and co-immunoprecipitation, the team showed that SESN3 interacts with the GATOR2 complex during starvation and that this interaction is disrupted by tryptophan but not by other amino acids, identifying SESN3 as a tryptophan sensor for the mTOR pathway in T cells.

In vivo work confirmed the physiological relevance. Transplanting genome-edited hematopoietic stem and progenitor cells into mice and inducing experimental autoimmune encephalomyelitis, a model of multiple sclerosis, the researchers observed accelerated onset of disease symptoms and weight loss in animals lacking Sesn3, along with increased infiltrating activated T cells in the central nervous system. Together, the findings demonstrate that a common noncoding variant can promote autoimmunity through a gain-of-function CTCF mechanism that silences a metabolic sensor of immune homeostasis, a mechanism the authors note could only have been fully resolved with high-resolution, allele-specific chromatin mapping. Because genetic evidence is known to increase the probability of clinical trial success roughly 2.6-fold, the team argues that MCCv, which can already capture 405 sites in parallel and could plausibly exceed 1,000 targets per experiment, offers a scalable route from GWAS catalogs to validated causal variants, genes and therapeutic targets.

Subject of Research: Allele-specific nanoscale chromatin architecture mapping to identify causal noncoding regulatory variants in inflammatory disease

Article Title: Single-allele nanoscale mapping of regulatory variants

Article References: Hamley, J. C., Zhang, W., Willmott, D., Chen, L. Y., Sharlandjieva, V., Li, H., Dalgleish, J. L. T., Denny, N., Agarwal, G., Hentges, L., Ozcan, B., Doll, R. M., Wei, Y., Riva, S. G., Venkatesh, S. S., Arachi, M., Agarwal, D., Akkuratov, E. E., Baxter, M., … Davies, J. O. J. (2026). Single-allele nanoscale mapping of regulatory variants. Nature Genetics, 58(10), 2660-2672. https://doi.org/10.1038/s41588-026-02776-8

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02776-8

Keywords: MCCv, Micro Capture-C, noncoding variants, chromatin architecture, CTCF, super-enhancer, SESN3, mTOR signaling, autoimmunity, GWAS, CD4 T cells, genome editing

Transcription factors are proteins that bind specific DNA sequences and influence which genes are read into RNA. Most act on chromatin that is already accessible, but the review emphasizes that Gata2 belongs to a special class called pioneer factors. Pioneer factors can invade condensed, chemically silenced stretches of DNA that other proteins cannot reach, prying the chromatin open and creating landing pads for the rest of the gene-regulatory machinery. In the developing embryo, this ability is what allows Gata2 to initiate the program that converts vascular cells into blood cells, a process known as the endothelial-to-hematopoietic transition, or EHT. Without Gata2, mice die around embryonic day 10.5, unable to generate the first definitive blood stem cells.

Runx1, the partner in the axis, operates on a slightly later schedule. Mouse embryos lacking Runx1 survive a day longer, dying between embryonic days 11.5 and 12.5, and the review argues that this offset in lethality reflects genuinely different temporal and tissue requirements rather than a simple hierarchy between the two factors. Runx1 is indispensable for the moment when hemogenic endothelial cells lining the dorsal aorta physically transform into hematopoietic cells, forming intra-aortic clusters that seed the future blood system. Once blood stem cells are established in the adult, however, the picture changes: Gata2 becomes the guardian of stem cell maintenance and survival, while Runx1 is more involved in driving differentiation, particularly along the megakaryocyte lineage, and in restraining stem cell quiescence programs.

The technical heart of the review lies in how these two factors remodel the three-dimensional genome. DNA in the nucleus is not a linear string; it is folded into loops and organized into topologically associating domains, or TADs, within which enhancers preferentially contact their target genes. Runx1 participates in reshaping these domains and in modulating enhancer-promoter interactions, recruiting effector proteins such as the chromatin remodeler CHD7 and the TET family of DNA demethylating enzymes. CHD7, according to work the review highlights, provides a kind of braking mechanism on hematopoietic differentiation, ensuring that Runx1-bound loci are prepared but not prematurely activated. Meanwhile, TET enzymes convert 5-methylcytosine to 5-hydroxymethylcytosine, actively erasing DNA methylation marks at genes that must be switched on for blood development.

One of the most conceptually interesting sections concerns the Runx1 +23 enhancer, a highly conserved intronic regulatory element that functions as a super-enhancer, a dense cluster of enhancer sequences bound by unusually high levels of transcriptional machinery. This element integrates inputs from Gata, Ets, and SCL transcription factor families to trigger Runx1 expression at precisely the moment HSCs must emerge. The authors describe a feed-forward loop in which Gata2 acts as the initiator, opening chromatin at such enhancers so that Runx1 and its cofactors can bind and consolidate the program. Cooperation and competition between the two factors, they argue, are not rival descriptions of the axis but different behaviors at different classes of regulatory element, with redundancy that is directional, dose-graded, and even species-dependent, as zebrafish and mouse studies demonstrate.

When this finely tuned system breaks, the consequences are catastrophic, and the review frames them under the vivid concept of epigenetic addiction. Myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes, frequently arise not from mutations in the coding sequence of Runx1 or Gata2 themselves but from disruptions to the epigenetic architecture they maintain. Hypermethylation of regulatory DNA can silence the axis; haploinsufficiency, the loss of one functional copy of Gata2, destabilizes chromatin looping and predisposes carriers to immunodeficiency, bone marrow failure, and leukemia; and enhancer hijacking can rewire the genome entirely. A famous example cited in the literature is a single oncogenic enhancer rearrangement that simultaneously deregulates EVI1 and GATA2, driving an aggressive leukemia with one structural change.

The three-dimensional view of leukemia is reinforced by studies of the cohesin complex, the ring-shaped protein assembly that physically anchors chromatin loops. Mutations in cohesin components such as STAG2, combined with RUNX1 deficiency, synergistically perturb chromatin looping and produce myelodysplastic syndromes. Cohesin mutants appear to lock cells into a stem-cell-like program by altering chromatin accessibility in ways that mimic, and corrupt, the pioneer-factor landscape that Gata2 normally curates. GATA2 has even been shown to perform mitotic bookmarking, preserving regulatory memory through cell division, and to decommission enhancers that would otherwise amplify inflammatory signaling, a newly appreciated mechanism constraining inflammation in hematopoietic progenitors.

What elevates the review beyond a descriptive synthesis is its treatment of therapy. Because malignant clones in AML and MDS are epigenetically addicted to their distorted chromatin states, the authors argue, those states are also therapeutic vulnerabilities. Existing demethylating agents, such as hypomethylating drugs used in myelodysplastic syndromes, exploit this dependence by partially reversing aberrant methylation. More futuristic approaches include CRISPR-Cas9-mediated epigenetic editing, in which programmable molecular tools are directed to specific enhancers to rewrite their histone marks or methylation status without cutting the DNA, and super-enhancer targeting, which aims to collapse the transcriptional hubs that sustain oncogenic programs such as RUNX1-driven T-cell leukemia. The goal in every case is the same: restore proper chromatin architecture to the malignant clone and return it to a controllable state.

The timing of such interventions matters enormously, and the review is careful about dose. Both too little and too much GATA2 are harmful; enforced overexpression blocks normal hematopoiesis, while low-level overexpression promotes myeloid progenitor self-renewal at the expense of lymphoid differentiation. Similarly, Runx1 isoforms show differential expression during development yet overlapping functions in adult stem cells, and DNA methylation of Runx1 regulatory regions correlates with the transition from primitive to definitive blood potential. Any therapeutic strategy that manipulates the axis must therefore respect the narrow dosage window within which healthy hematopoiesis operates, a constraint the authors treat as a central design principle rather than a footnote.

For a field increasingly populated by single-cell atlases, the review also points to methodological frontiers. Techniques such as single-cell RNA sequencing, single-cell ATAC-seq for chromatin accessibility, and new platforms that jointly profile multiple epigenetic proteins and transcription in the same cell are making it possible to watch the Runx1-Gata2 axis operate in individual cells as they commit to fate. Combined with barcoding technologies that trace the real-life fates of hematopoietic stem cells in vivo, these tools are converting what was once a static network diagram into a dynamic, quantifiable choreography. The Runx1-Gata2 axis, as Mallick and Chakraborty present it, is best understood not as a pair of genes but as an epigenetic operating system, one whose architecture, when faithfully maintained, builds the blood, and whose corruption, when left unrepaired, builds leukemia.

Subject of Research: Epigenetic regulation of hematopoietic lineage fate by the Runx1-Gata2 transcription factor axis

Article Title: The Runx1-Gata2 axis: epigenetic architecture of lineage fate

Article References: Mallick, S., & Chakraborty, A. (2026). The Runx1-Gata2 axis: epigenetic architecture of lineage fate. Molecular Biology Reports, 53(1), Article 1643. https://doi.org/10.1007/s11033-026-12742-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12742-6

Keywords: Runx1, Gata2, epigenetics, hematopoietic stem cells, chromatin, transcription factors, acute myeloid leukemia, myelodysplastic syndrome, pioneer factor, super-enhancer, TET enzymes, CRISPR epigenetic editing

Super-enhancers are unusually large clusters of regulatory DNA sequences bound by high concentrations of transcription factors and co-activators. Unlike ordinary enhancers, which may boost the expression of a single nearby gene, super-enhancers often orchestrate entire cellular identity programs, and in cancer they are frequently hijacked to drive tumor-promoting gene networks. Because these regions are highly accessible, meaning the chromatin there is open and biochemically active, they are prime candidates for studying how genetic variation influences cancer risk and progression. Yet, as the authors of the new study note, the consequences of genomic variants within super-enhancers have remained poorly understood.

The team focused on a regulatory element they describe as bifunctional: a single super-enhancer that simultaneously controls the expression of two genes with very different biochemical outputs. One is LINC00636, a long non-coding RNA, a transcript that is copied from the genome but is not translated into a protein. The other is CD47, a well-known cell-surface protein often called a do-not-eat-me signal because it protects cells from being engulfed by immune cells called macrophages. CD47 is overexpressed in many cancers and has been a major target of experimental immunotherapies. The finding that one super-enhancer governs both a long non-coding RNA and a key immune-evasion molecule immediately suggested a mechanism by which a single DNA change could have layered effects on tumor biology.

Within this super-enhancer, the researchers identified a common germline insertion-deletion variant, or InDel, meaning that some people carry an extra segment of DNA inserted at this position while others do not. Germline variants are inherited and present in every cell of the body, in contrast to the somatic mutations that accumulate during tumor development. The team found that the insertion allele was associated with reduced chromatin accessibility at the super-enhancer locus. In practical terms, when the extra DNA segment is present, the regulatory region appears to be less open, and its activity is dialed down. Chromatin accessibility is a critical variable in gene regulation: open chromatin allows transcription factors and co-activators to bind, while closed chromatin locks them out.

To test whether this correlation reflected a causal relationship, the scientists used gene-targeting techniques to delete the insertion from breast cancer cells grown in the laboratory. The results were unambiguous. Removing the insertion increased chromatin accessibility at the super-enhancer, and this was followed by upregulation of both LINC00636 and CD47. In other words, the insertion acts as a kind of molecular brake on the super-enhancer, and removing the brake lets the two cancer-promoting genes run at higher levels. This experimental design, comparing otherwise identical cells that differ only at the InDel, allowed the researchers to isolate the effect of the variant from the thousands of other genetic differences that normally exist between individuals.

The downstream consequences of deleting the insertion revealed two distinct tumor-promoting programs. The first was mediated by CD47. With more CD47 on their surfaces, the engineered breast cancer cells showed enhanced resistance to apoptosis triggered by nutrient deprivation, the programmed self-destruction that cells normally undergo when starved of essential supplies. Tumors frequently face harsh metabolic conditions as they outgrow their blood supply, and the ability to survive nutrient stress is a recognized hallmark of aggressive cancer. The study’s data indicate that a common inherited variant in a super-enhancer can influence this survival trait through its effect on CD47 expression.

The second program was driven by elevated LINC00636. When the long non-coding RNA was increased, the cells showed activation of senescence, a state in which cells stop dividing but remain metabolically active and often secrete inflammatory signals. Senescence has a complicated relationship with cancer: it can suppress tumor growth directly, but senescent cells in the tumor microenvironment can also promote malignancy through the molecules they release. The authors report that this study establishes a previously unrecognized role for LINC00636 in senescence and breast cancer biology, making the long non-coding RNA a newly identified player in the disease rather than a genomic bystander.

The variant also appeared to reshape the immune landscape around tumor cells. Cells lacking the insertion, and therefore expressing higher levels of CD47, showed reduced infiltration by CD80-positive pro-inflammatory macrophages, the immune cells that help mount an attack against tumors. This observation connects the InDel to the tumor microenvironment, the ecosystem of immune and stromal cells that surrounds a cancer. A single inherited DNA change, by modulating a do-not-eat-me signal, may therefore influence not only how tumor cells behave in isolation but also how the immune system perceives and responds to them.

Taken together, the authors conclude that the insertion allele appears to have a protective role, since its presence dampens the activity of a super-enhancer driving cancer-promoting features. The findings carry several broader implications. For one, they demonstrate that common germline variation within super-enhancers can fine-tune regulatory output in ways that matter for cancer biology, extending the search for functional variants well beyond protein-coding regions and even beyond ordinary promoters and enhancers. For another, the bifunctional nature of the super-enhancer means that a single variant simultaneously influences an immune-evasion gene, a stress-resistance pathway, a senescence program, and immune-cell infiltration, illustrating how compact and interconnected the architecture of cancer gene regulation can be.

The study, which was funded in part by the NIH National Cancer Institute, the California Breast Cancer Research Program, and the Breast Cancer Research Foundation-AACR Career Development Awards, was published as an open-access article and is citable under the DOI 10.1007/s00018-026-06456-y. While the work was performed primarily in cell models and will need to be extended to patient cohorts to determine whether the insertion allele correlates with clinical outcomes, it provides a concrete mechanistic framework for a question that has long hovered over cancer genomics: what do the inherited variants in our non-coding DNA actually do? In this case, the answer is that a small insertion in a super-enhancer can quietly set the volume of two cancer genes at once, with consequences that ripple from chromatin structure all the way to the immune cells surrounding a tumor.

Subject of Research: A germline InDel variant within a bifunctional super-enhancer regulating LINC00636 and CD47 expression in breast cancer

Article Title: An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer

Article References: Di Benedetto, C., Tsark, A., Acenas, D., Thach, A., Singhal, A., Opazo-Mellado, V., Lemus, A. R., Zeini, M. E., Zhang, H., Park, C., Velozo, H. G., Weissmann, I., & Betancur, P. (2026). An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06456-y

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06456-y

Keywords: super-enhancer, InDel variant, LINC00636, CD47, breast cancer, chromatin accessibility, long non-coding RNA, senescence, macrophages, gene regulation, cancer genomics, tumor microenvironment